Biotech China 2014

View Profile


Grant Support

Start year End year Title Source Position
1. 2011 Present A phase II, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of MLTA3698A in combination with a disease-modifying anti-rheumatic drug (DMARD) compared with adalimumab in combination with a DMARD in patients with active rheumatoid arthritis Genentech PI
2. 2011 Present A long-term, open-label follow-up study of tasocitinib (CP-690,550) for treatment of rheumatoid arthritis (A3921024). Pfizer PI
3. 2010 Present A multi-center, continuation trial of belimumab (HGS 1006, LymphoStat-BTM), a fully human monoclonal anti-BLyS antibody, in subjects with systemic lupus erythematosus (SLE) who completed the phase 3 protocol HGS1006-C1056 in the United States Human Genome Sciences PI
4. 2012 2013 Validation of cathepsin S as a tear biomarker for Sjögren’s syndrome SC CTSI PI
5. 2012 The role of the BAFF axis in bleomycin-induced pulmonary fibrosis Laurel Foundation PI
6. 2012 The role of the BAFF axis in experimental autoimmune encephalomyelitis National Multiple Sclerosis Society PI
7. 2011 2012 Effect of XmAb5871, an FcgRIIb-enhanced anti-CD19 antibody, in rheumatoid arthritis Xencor PI
8. 2006 2012 The vital role for BAFF in the development of SLE. NIH PI
9. 2010 2011 A phase 3 randomized, double-blind study of the efficacy and safety of 2 doses of CP-690,550 compared to methotrexate in methotrexate-naive patients with rheumatoid arthritis Pfizer PI
10. 2010 2011 A phase 3 double-blind, placebo-controlled study of the efficacy and safety of 2 doses of CP-690,550 in subjects with rheumatoid arthritis on background methotrexate who have had inadequate response to prior TNF inhibitor therapy Pfizer PI
11. 2009 2010 Effect of XmAb5871, an FcgRIIb-enhanced anti-CD19 monoclonal antibody, in systemic lupus erythematosus Xencor PI
12. 2008 2010 The role for APRIL and its receptors in murine SLE. Arthritis Foundation Southern California Chapter PI
13. 2007 2010 A phase 3, multi-center, randomized, double-blind, placebo-controlled, 76-week study to evaluate the efficacy and safety of belimumab (HGS1006, LymphoStat-BTM), a fully human monoclonal anti-BLyS antibody, in subjects with systemic lupus erythematosus (SLE). Human Genome Sciences PI
14. 2006 2010 A randomized, phase 3 controlled, double-blind, parallel group, multicenter study to evaluate the safety and efficacy of rituximab in combination with methotrexate (MTX) compared to MTX alone, in methotrexate-naïve patients with active rheumatoid arthritis. Genentech PI
15. 2008 2009 A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis continuing methotrexate treatment Genentech PI
16. 2008 2009 A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis who have an inadequate response to at least one anti-TNF-a therapy Genentech PI
17. 2008 2009 A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab in combination with methotrexate (MTX) compared to MTX alone in methotrexate-naïve patients with active rheumatoid arthritis Genentech PI
18. 2005 2006 A randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AMG 623 following multi-dose administration in subjects with systemic lupus erythematosus Amgen PI
19. 2004 2006 A pilot efficacy study of BAFF-DN antagonists, administered by intraperitoneal injection to mice. Xencor PI
20. 2005 A multi-center, open-label, continuation trial of LymphoStat-B antibody (monoclonal anti-BLyS) in subjects with systemic lupus erythematosus (SLE) who completed the phase 2 protocol LBSL02 Human Genome Sciences PI
21. 2005 A multi-center, open-label, continuation of LymphoStat-B antibody (monoclonal anti-BLyS antibody) in subjects with rheumatoid arthritis (RA) who completed the phase 2 protocol LBRA01 Human Genome Sciences PI
22. 2004 2005 A phase II, multi-center, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, tolerability, and efficacy of LymphoStat-BTM antibody (monoclonal anti-BLyS antibody) in subjects with rheumatoid arthritis (RA). Human Genome Sciences PI
23. 2004 2005 A randomized, double-blind study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 623 following single-dose administration in subjects with systemic lupus erythematosus Amgen PI
24. 2004 2005 A phase II, multi-center, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, tolerability, and efficacy of LymphoStat-BTM antibody (monoclonal anti-BLyS antibody) in subjects with systemic lupus erythematosus (SLE). Human Genome Sciences PI
25. 2003 2005 A novel murine model of Sjögren's syndrome. Arthritis Foundation Southern California Chapter. PI
26. 2003 2004 A novel murine model of Sjögren's syndrome Robert E. and May R. Wright Foundation. PI
27. 2002 2003 Local expression and production of B lymphocyte stimulator protein in the joints of arthritis patients. Arthritis Foundation Southern California Chapter PI
28. 2002 2003 A phase I, multi-center, double-blind, single and double dose-escalation study to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of LymphoStat-BTM (monoclonal anti-BLyS antibody) in subjects with systemic lupus erythematosus Human Genome Sciences PI
29. 2001 2003 A multi-center study in subjects with systemic lupus erythematosus and rheumatoid arthritis to determine B-lymphocyte stimulator (BLyS) concentrations in relation to disease activity Human Genome Sciences PI
30. 2001 2002 Elevated B lymphocyte stimulator (BLyS) in HIV-infected patients: a harbinger of systemic immune-based rheumatic disease? Robert E. and May R. Wright Foundation. William Stohl, principal investigator Coordinator
31. 2001 2002 Serum levels of B lymphocyte stimulator (BLyS) in HIV-infected patients Human Genome Sciences PI
32. 2001 2002 Systemic lupus erythematosus: a blissless disease of unbridled BLyS (B Lymphocyte Stimulator). Alliance for Lupus Research PI
33. 1997 2002 T cell cytolytic activity in SLE (Competitive renewal) NIH (R01 AR41006) PI
34. 1998 2000 Microbial superantigen-dependent T cell-mediated downregulation of Ig responses: role of CD95- and perforin-based cytolytic pathways and their dysfunction in human SLE Arthritis Foundation Biomedical Science Grant PI
35. 1997 1998 Impaired microbial superantigen-dependent T cell-mediated cytolysis of activated B cells in human SLE Arthritis Foundation Southern California Chapter PI
36. 1996 1997 In vivo regulation of B cells by NK1+ cells. Robert E. and May R. Wright Foundation. PI
37. 1993 1997 T cell cytolytic activity in SLE. NIH (R01 AR41006). PI
38. 1995 1996 Impaired regulation of polyclonal antibody production induced by microbial superantigens in systemic lupus erythematosus Arthritis National Research Foundation PI
39. 1989 1992 Differential human T cell activation pathways Arthritis Foundation Arthritis Investigator Award PI
40. 1989 1991 Aberrant T cell activation in systemic lupus erythematosus Lupus Foundation of America. PI
41. 1989 1991 T cell activation in immunodeficiency disorders. March of Dimes Birth Defects Foundation PI
42. 1989 1990 Activation and regulation of interleukin 2 production in human T cells. USC School of Medicine Biomedical Research Support Grant. PI
43. 1987 1990 T cell activation and T cell-dependent B cell activation in systemic lupus erythematosus The Victoria Principal Research Grant of the Arthritis Foundation Southern California Chapter PI
44. 1989 Differential induction of interferon-gamma and MHC-unrestricted cytotoxicity by anti-CD3 monoclonal antibodies USC Comprehensive Cancer Center PI
45. 1988 1989 T cell activation pathways in systemic lupus erythematosus Lupus Foundation of America. PI
46. 1985 1989 Polymorphism within T4/Leu3 and SLE NIH New Investigator Award PI
47. 1987 1988 T cell activation and T cell-dependent B cell activation in SLE Lupus Foundation of America. PI
48. 1987 1988 T cell activation and T cell dependent B cell activation in SLE USC School of Medicine Biomedical Research Support Grant. PI


4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.